Abstract:Chemotherapy with Docetaxel (Doc) is efficient in a subset of prostate cancer (PCa) cases; however, most patients ultimately develop resistance to Docetaxel. The tumor immune microenvironment and secreted cytokines play a substantial role in development of resistance to chemotherapy. Our previous study has demonstrated that CD4+ T cells in prostate tumor microenvironment contribute to PCa progression; meanwhile, we found increased CD4+ T‐cell infiltration in tumor area after Doc treatment; however, their effects on PCa chemosensitivity remain unclear. Here, we aim to explore the role and mechanisms of CD4+ T cells in PCa chemotherapy sensitivity.CD4+ T‐cell infiltration in Doc‐treated paraffin‐embedded specimens from transurethral resection of prostate, radical prostatectomy, or bone metastasis was detected by immunohistochemistry. The castration‐resistant PCa cell lines—C4‐2 and CWR22RV1, and CD4+ T‐cell lines—HH and Molt‐3 were used in the coculture system. After coculture with the lymphocytes, PCa cell chemosensitivity was detected by cell counting kit‐8, terminal deoxynucleotidyl transferase dUTP nick‐end labeling assays, and Western blot analysis. Various cell cytokines were determined by cytokine arrays and reverse‐transcription polymerase chain reaction. The recombinant human C‐C motif chemokine ligand 5 (CCL5) was added to PCa cells for further confirming its effects and anti‐CCL5 antibody was used for neutralization. S3I‐201, a signal transducer and activator of transcription 3 (STAT3) inhibitor, was added to the coculture system to detect STAT3 role in chemosensitivity. Tumor xenografts in nude mice were used for confirming effects of CD4+ T cells in vivo study.We found more infiltrated CD4+ T cells in human PCa lesions than in the adjacent noncancerous tissues after Doc treatment. In vitro cell line study confirmed that CD4+ T cells increase the PCa Doc resistance. Quantative polymerase chain reaction and cytokine arrays indicated that after coculture with PCa, CD4+ T cells could secrete large amounts of CCL5. Moreover, CCL5 stimulation enhanced PCa resistance to Doc, and anti‐CCL5 antibody could partly reverse this process. We found that CD4+ T cells could activate P‐STAT3 signaling via secreting CCL5 and adding a STAT3 inhibitor can reverse the chemoresistance. In vivo mouse model with xenografted 22RV1 cells and CD4+ T cells also confirmed the in vitro results.Together, our results indicate that infiltrating CD4+ T cells could promote PCa chemotherapy resistance via modulation of the CCL5/STAT3 signaling pathway.

Sox2 is involved in paclitaxel resistance of the prostate cancer cell line PC-3 via the PI3K/Akt pathway.

Targeting XPO6 Inhibits Prostate Cancer Progression and Enhances the Suppressive Efficacy of Docetaxel

Nkx3.1 and P27kip1cooperate in Proliferation Inhibition and Apoptosis Induction in Human Androgen–Independent Prostate Cancer Cells

Sox2 targets cyclinE, p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis.

SOX2 Regulates Paclitaxel Resistance of A549 Non‑small Cell Lung Cancer Cells Via Promoting Transcription of ClC‑3

SOX2 Promotes Tumorigenesis and Increases the Anti-Apoptotic Property of Human Prostate Cancer Cell.

Establishment and Characterization of a Docetaxel-Resistant Human Prostate Cancer Cell Line.

Saikosaponin-d mediates FOXG1 to reverse docetaxel resistance in prostate cancer through oxidative phosphorylation

Inhibition of Notch Pathway Enhances the Anti-Tumor Effect of Docetaxel in Prostate Cancer Stem-Like Cells

Cancer Therapy : Preclinical The Mechanism of DAB 2 IP in Chemoresistance of Prostate Cancer Cells

Sox2 is Necessary for Androgen Ablation-Induced Neuroendocrine Differentiation from Pten Null Sca-1+ Prostate Luminal Cells

Overexpression Of Bcl-X-L Underlies The Molecular Basis For Resistance To Staurosporine-Induced Apoptosis In Pc-3 Cells

Abstract 1216: the Mechanism Related to Anti-Apoptotic Property of SOX2 in Prostate Cancer

SOX8 Affects Tumoral SPARC Expression by Regulating EZH2 to Attenuate Effectiveness of albumin-bound paclitaxel in PDAC

Sox2 Inhibits Wnt-β-catenin Signaling and Metastatic Potency of Cisplatin-Resistant Lung Adenocarcinoma Cells

CLC-3 and SOX2 Regulate the Cell Cycle in DU145 Cells

INPP4B Reverses Docetaxel Resistance and Epithelial-to-mesenchymal Transition Via the PI3K/Akt Signaling Pathway in Prostate Cancer.

Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling

The Key Cellular Senescence Related Molecule RRM2 Regulates Prostate Cancer Progression and Resistance to Docetaxel Treatment

NOTCH1 signaling promotes chemoresistance via regulating ABCC1 expression in prostate cancer stem cells

The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer